Drug combination extends pancreatic cancer patient survival, study suggests
Tuesday, January 22, 2013 - 21:30
in Health & Medicine
A multi-center Phase III clinical trial demonstrates that Abraxane (nab-paclitaxel) plus gemcitabine is the first combination of cancer drugs to extend survival of late-stage pancreatic cancer patients compared to standard treatment.